← Back to Home

GenScript’s First-Half Revenue Rises 27.3% as AI Drug Discovery Drives Demand for Laboratory Services

Computer-designed candidate molecules still need to enter the laboratory. GenScript’s half-year results show demand for gene synthesis and protein production services from AI drug discovery, while leaving questions about research and development outcomes unresolved.

By SURL BioNews

After AI generates more candidate molecules, who will make them and test whether they are usable? GenScript Biotech’s results for the first half of 2026, announced on August 18, bring the laboratory services behind drug discovery into focus. The company said its AI-related drug discovery business doubled from the same period last year, with demand coming from AI biotech companies and pharmaceutical research and development clients.

On the comparable basis reported by the company, first-half revenue was approximately US$404.2 million, up 27.3% year over year. This reflects the financial performance of the overall business, and the increase cannot be attributed entirely to AI; the company also attributed growth to expansion of its core businesses and improvements in operational efficiency.

The Gene-to-Protein business accounted for approximately 66% of revenue at GenScript’s Life Science Group. This service integrates gene synthesis, protein production and antibody discovery, helping clients turn designs into materials for experimental testing. The denominator for this share is the life science business, rather than the entire group.

For biomedical applications, these services handle the work that follows computational design: candidate proteins or antibodies must be produced and experimentally evaluated before research and development teams can decide whether to invest further. According to the company, increased demand for protein engineering and biologic drug discovery drove growth in the related businesses.

However, the results announcement did not provide comparable model datasets, candidate molecule hit rates or clinical validation results, nor did it disclose a separate revenue figure for AI-related business. The doubling of business therefore indicates expanding demand for services, but is not yet sufficient to determine whether AI has improved drug development success rates.

The industry signal in these financial results is that expanding computational capacity may bring more experimental work. For GenScript, the commercial opportunity lies in meeting these validation needs; for drug research and development, the next hurdle is to establish whether increased investment in experiments can produce more reliable therapeutic candidates worth advancing.

References

  1. TradingView